Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Eribulin normalizes pancreatic cancer-associated fibroblasts by simulating selected features of TGFβ inhibition

Fig. 4

Eribulin-treated CAFs generate tumor-suppressive ECMs. A Illustration showing cancer cells re-plated onto decellularized CDMs obtained from eribulin-treated CAFs. B Representative 4x microscopy images of RFP-expressing Panc-1 spheroids that were allowed to spread for 24 h (using nutrient-avid conditions) onto CDMs generated by CAFs treated with DMSO, eribulin, SB431542, or paclitaxel. Scale bar corresponds to 500 μm (white), while average spheroid spread radiuses (r) are shown in yellow for control and red for experimental conditions. The corresponding graph, on the right, shows 24 h/0hr ratios of measured mean-radiuses. For statistical significance, the Mann-Whitney test was used to compare each condition to the DMSO veh. control. * P < 0.05; ** p < 0.01; *** P < 0.001; **** p < 0.0001. C RFP-expressing Panc-1 cells were cultured into the assorted listed decellularized CDMs, as in B, only this time using nutrient-deprived conditions. Viable cells were gauged following 24, 48, and 72 h and representative 24-hour images are shown, while 48 and 72 h are in Supplemental Fig. 6. Scale bar corresponds to 100 μm. The graph indicates the percentage of survival, represented by RFP-expressing Panc-1 cells. Area coverage obtained data were normalized to DMSO veh., which average was set as 100% survival. For statistical significance, a one-way ANOVA (Turkey’s multiple comparisons) test was used to compare all conditions. Black asterisks denote comparisons to DMSO, while the eribulin vs. paclitaxel comparison is noted in orange. * P < 0.05; ** p < 0.01; *** P < 0.001; **** p < 0.0001

Back to article page